Clinical Trial: A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164534) titled 'A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.' on Sept. 01.

Brief Summary: Cervical cancer is the second most common cancer in Indian women, and most patients are diagnosed at advanced stages.

The standard treatment for these stages is concurrent chemoradiotherapy, but this can cause long-term side effects such as bladder inflammation, strictures, ulcers, and tissue damage, which negatively impact patients' quality of life.

Previous studies have shown that oral sodium-copper-chlorophyllin can help reduce r...